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Featured Application: Development of topical formulations based on lipid nanoparticles for the
treatment of skin aging and diseases involving cutaneous dryness and scaling such as atopic and
exfoliative dermatitis and psoriasis.
Abstract: Idebenone (IDE) is a strong antioxidant that has been proposed for the treatment of skin
disorders, including skin ageing. Unfavorable physico-chemical properties make IDE a poor skin
permeant where effectiveness could be improved by its loading into suitable delivery systems such
as solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC). In this work, we designed
novel IDE-loaded NLC containing tocopheryl acetate (VitE) as a liquid component to obtain a
synergic effect between IDE and VitE. The resulting NLC showed small particle sizes (24–42 nm), low
polydispersity indices (<0.300), good stability, and were assessed for their in vitro antioxidant activity
and in vivo topical effects. IDE-loaded SLN and NLC showed a high antioxidant activity in in vitro
assays (DPPH and reducing power method) and provided a similar and significant protection from
oxidative stress of fibroblast cells, HS-68, exposed to UV light. After a two-week topical treatment of
human volunteers with gels containing IDE-loaded SLN or NLC, a similar increase in skin hydration
was observed, while IDE NLC reduced skin pigmentation to a greater extent than IDE SLN. These
results suggest that co-loading IDE and VitE into NLC could be a promising strategy to obtain topical
formulations with improved photo-protection.
Keywords: Idebenone; tocopheryl acetate; lipid nanoparticles; antioxidants; topical administration;
skin hydration; photo-protective effect
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1. Introduction
In the last decades, solid lipid nanoparticles (SLNs) have been widely investigated as carriers
for topical drug delivery [1–7]. These colloidal systems, consisting of a solid lipid matrix stabilized
by different types of surfactants, have been proposed for skin delivery of various active ingredients
including antifungal, anticancer, anti-inflammatory, and antioxidant agents [8–15]. The interest in
SLNs arises from their many advantages compared to other colloidal carriers such as possibility
of incorporating both hydrophilic and lipophilic drugs, ability to achieve drug-controlled release
and targeting, thus improving drug topical bioavailability while reducing systemic side effects [1,4].
However, the highly ordered structure of the solid lipid matrix of SLN could result in low incorporation
of lipophilic drugs and drug leakage during storage. To overcome these drawbacks, liquid lipids were
mixed together with solid lipids to obtain a less packed lipid matrix, leading to a second generation
of lipid nanoparticles defined as nanostructured lipid carriers (NLC) [2,3,6]. To obtain this last type
of nanocarrier, a variety of oils without any intrinsic pharmacological activity has been investigated.
However, to improve NLC effectiveness, oils that have a synergic activity with the loaded drug could
be used together with solid lipids to form the NLC core.
Previously, we evaluated in vitro skin permeation of idebenone (IDE), an analogue of coenzyme
Q10 with strong antioxidant activity [16], from SLNs with different compositions [17]. We observed
an interesting IDE-targeting effect in the upper skin layers from SLNs prepared using oleth-20 as a
surfactant and cetyl palmitate as the solid lipid. These SLNs showed good stability during storage at
room temperature but limited IDE loading.
In this work, we designed IDE-loaded nanoparticles (NLC) containing tocopheryl acetate (vitamin
E acetate, VitE) as a liquid component to obtain both a synergic effect between IDE and VitE and to
improve IDE loading. Vitamin E is a well-known radical scavenger agent with skin photo-protective
properties [18] for which topical beneficial effects are well known [19].
To evaluate the effect of co-loading vitamin E acetate and IDE in the matrix of lipid nanoparticles,
we assessed technological properties, in vitro antioxidant activity, and cytotoxic and photo-protective
effects of IDE loaded SLN and NLC on human fibroblast cells HS-68. In addition, we evaluated the
effects of topical application on human volunteers of gel formulations containing IDE-loaded SLN
and NLC.
2. Materials and Methods
2.1. Materials
Glyceryl oleate (Tegin O®, GO), cetyl palmitate (CP), methylisothiazolinone and
methylchloroisothiazolinone (Acnibio AC®), and triethanolamine (TEA) were bought from
ACEF (Fiorenzuola D’Arda, Italy). Idebenone (IDE) was obtained from Carbosynth (Berkshire,
UK). Polyoxyethylene-20-oleyl ether (Brij 98®, Oleth-20) and tocopheryl acetate (VitE) was
obtained from Farmalabor (Canosa di Puglia, Italy). Potassium ferricyanide and trichloroacetic
acid were bought from Carlo Erba reagents (Milano, Italy). Gallic acid, iron (III) chloride (FeCl3),
2,2-Diphenyl-1-picrylhydrazyl (DPPH), human skin fibroblasts (Sigma®HS68), Dulbecco’s Modified
Eagle’s Medium (DMEM), fetal bovine serum, glutamine, and penicillin–streptomycin were obtained
from Merck KGaA (Darmstadt, Germany).
2.2. Preparation of Lipid Nanoparticles (SLN and NLC)
Lipid nanoparticles (SLN and NLC) were prepared using the phase inversion temperature (PIT)
method [20], and their composition is illustrated in Table 1. The aqueous phase consisted of deionized
water containing preservatives (Acnibio AC®0.05% w/w and Kemipur 100®0.35 % w/w) to prevent
microbial growth during storage. Unloaded and drug-loaded lipid nanocarriers were prepared using
the same procedure. Briefly, after heating the oil phase and aqueous phase separately at 90 ◦C,
the aqueous phase was added dropwise to the oil phase under vigorous stirring (700 rpm). While
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cooling down to room temperature, at the phase inversion temperature (PIT), the colloidal suspension
turned clear and the PIT value was recorded using a conductivity meter (model 525, Crison, Modena,
Italy). The resulting samples were stored in airtight jars at room temperature in the dark until used.
Table 1. Composition of the oil phase of lipid nanoparticles. GO = glyceryl oleate; CP = cetyl palmitate;
VitE = tocopheryl acetate, IDE = idebenone, SLN = solid lipid nanoparticles, NLC = nanostructured
lipid carriers.
Code
Ingredients (% w/w) *
Oleth-20 GO CP VitE IDE
SLN 9.00 5.00 7.00 - -
SLN IDE1 9.00 5.00 7.00 - 1.00
SLN IDE1.5 9.00 5.00 7.00 - 1.50
NLC 9.00 5.00 6.00 1.00 -
NLC IDE1 9.00 5.00 6.00 1.00 1.00
NLC IDE1.5 9.00 5.00 6.00 1.00 1.50
* Water phase q.s. 100.00%
2.3. Transmission Electron Microscopy (TEM)
The morphology of SLN and NLC was assessed by transmission electron microscopy (TEM)
analysis. Samples of each colloidal suspension (5 µL) were placed on a Formvar (200-mesh) copper
grid (TAAB Laboratories Equipment, Berks, UK). After sample absorption, the excess was removed by
filter paper, and a drop of 2% (w/w) aqueous solution of uranyl acetate was added. Then, the surplus
was removed, and the sample was allowed to dry at room temperature. Analyses were performed
with a transmission electron microscope (model JEM 2010, Jeol, Peabody, MA, USA) operating at an
acceleration voltage of 200 KV.
2.4. Photon Correlation Spectroscopy (PCS)
The mean particle size and the size distribution (polydispersity index, PDI) of each colloidal
suspension were determined by dynamic light scattering (DLS) using a Zetasizer Nano ZS90 (Malvern
Instruments, Malvern, UK) with a 4 mW laser diode at 670 nm and scattering light at 90◦.
All samples were analyzed after dilution (1:5, sample:distilled water) and allowed to reach 25 ◦C
for 2 min prior to the analysis. All measurements were carried out in triplicate, and the results were
expressed as mean ± SD. ζ-potential was determined by laser Doppler velocimetry using the same
Zetasizer reported above. All samples were diluted with KCl 1 mM (pH 7.0) before analysis [21].
2.5. Differential Scanning Calorimetry (DSC)
SLN and NLC samples were analyzed by DSC using a Mettler TA STARe instrument (Mettler
Toledo, Greifensee, Switzerland) equipped with a DSC 822e cell and a Mettler STARe V8.10 software.
Indium and palmitic acid (purity ≥ 99.95% and ≥ 99.5%, respectively; Fluka, Buchs, Switzerland)
were used to calibrate the instrument. For each sample, 100 µL was sealed into a calorimetric pan, and
DSC analyses were carried out by heating the sample from 5 to 65 ◦C (rate: 2 ◦C/min) and then cooled
from 65 to 5 ◦C (rate: 4 ◦C/min) for at least three times. A pan filled with 100 µL of the aqueous phase
used for lipid nanocarrier preparation was used as the reference. To calculate the sample crystallinity
index (CI), the melting enthalpy of the lipid in the nanocarriers was expressed as a percentage of the
melting enthalpy of the bulk lipid cetyl palmitate, which was considered totally crystalline as reported
in previous works [22,23]. VitE CI was taken equal to zero as this compound was liquid at room
temperature and did not show any melting peak. Each experiment was run in triplicate.
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2.6. Stability Tests
Samples of each colloidal suspension were stored at room temperature, protected from light
exposure, for two months. Particle sizes, PDI, and ζ-potential values were measured at intervals (24 h,
one week, two weeks, one month, and two months).
2.7. Reducing Power
The reducing power of the samples under investigation was determined according to the method
by Falleh [24]. Sample solutions at different concentrations (300 µL) were mixed with phosphate
buffer (300 µL, 0.2 M, pH 6.6) and potassium ferricyanide [K3Fe(CN)6] (300 µL, 1%); the mixture
was incubated at 50 ◦C for 20 min. A portion (300 µL) of trichloroacetic acid (10%) was added to the
mixture, which was then centrifuged at 3000 rpm for 10 min. The upper layer of solution (300 µL) was
mixed with distilled water (300 µL) and FeC13 (600 µL, 0.1%), and the absorbance was measured at
700 nm against gallic acid as the authentic standard. An increased absorbance of the reaction mixture
indicated increased reducing power. The EC50 value (mg mL−1) is the effective concentration of the
extract at which the absorbance was 0.5 and was obtained from linear regression analysis [24].
2.8. DPPH Radical Scavenging Activity
In this assay, gallic acid was used as a positive control. Different aliquots of sample were taken,
and the volume was made to 1.0 mL with ethanol. The reaction was started by the addition of a 1.0 mL
solution of 200 µM DPPH solution in ethanol. The reaction mixture was kept at room temperature for
30 min, and the absorbance was measured at 517 nm [25]. Scavenging activity was determined by the
following equation:
Scavenging activity = [1 − (Absorbance sample/Absorbance control)] × 100 (1)
2.9. Cell Culture
Human skin fibroblasts (Sigma®HS68) were cultured as monolayers in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM glutamine, and
100 µg/mL penicillin–streptomycin, and incubated in a humidified atmosphere at 5% CO2, 95%
air, and 37 ◦C. All cell culture methods were performed under sterile conditions using a grade II
flow hood.
2.10. Evaluation of Cytotoxicity and Photo-Protective Effect in Fibroblast Cell Line HS-68
Confluent cells were trypsinized and seeded in a 96-well plate at a concentration of 7 × 103
cells/well and incubated for 24 h. Preliminary experiments on fibroblast cells were directed toward
the evaluation of effects of different doses of IDE on cell vitality and the individuation of the adequate
range of compound concentrations to perform experiments of oxidative stress induction. Different
concentrations of IDE (10–100 µg/mL dissolved in 0.1% ethanol) were added to previously seeded
cells on a 96-well plate and left to incubate for 24 h, and afterward, the viability of cells was assessed.
Subsequently, cells were treated for 24 h with an amount of IDE-loaded SLN and NLC corresponding
to the highest IDE concentration that did not lead to cytotoxic effects (25 µg/mL). Then, the cells
were exposed to UV radiation (lamp UVB KW 254 nm) and left to incubate at 37 ◦C for 30 minutes,
according to Saija et al. [26] The viability of cells was measured using the MTT method according to
Mossman [27]. Results were expressed as a percentage of viable cells in respect to the negative control.
Each experiment of viability was carried out in triplicate.
2.11. Gel Preparation
To prepare gel formulations, Carbopol Ultrez 21 (0.8 % w/w) was used as a rheological additive,
and TEA (1.00% w/w) was used as a neutralizing agent. Carbopol Ultrez 21 was dispersed in the
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aqueous phase consisting of deionized water containing 0.35% w/w Kemipur 100 and 0.05% Acnibio
AC (gel C), unloaded SLN (gel SLN), SLN IDE1 (gel SLN IDE1), SLN IDE1.5 (gel SLN IDE 1.5),
unloaded NLC (gel NLC) NLC IDE1 (gel NLC IDE1), and NLC IDE1.5 (gel NLC IDE1.5). Owing to
IDE’s poor water solubility, we could not prepare a gel containing only free IDE as a control, not even
by adding low amounts of solubilizing agents to the vehicle. Full polymer hydration was obtained by
maintaining the mixture in the dark at room temperature for 24 h. Formulations were made viscous by
adding TEA (1.00 % w/w) drop by drop under slow mixing to avoid air bubble formation. All gels
were stored in airtight jars at room temperature and in the dark to protect from photo-degradation
until use. These gels were inspected for any changes in their organoleptic properties during storage
for one month at room temperature and in the dark.
2.12. In Vivo Evaluation of Gel Formulations
In vivo topical efficacy under in use conditions of unloaded and IDE-loaded SLN and NLC was
assessed according to a protocol previously described [11,12,28]. Fourteen female subjects with average
photo-aging were selected (age range: 45–63 years) and experiments were performed according to the
rules of the Declaration of Helsinki of 1975, revised in 2008. The local ethics committee declared that
this type of study did not require any approval due to its nature and the safety of the formulations
under investigation.
All volunteers provided their written informed consent after being informed of the nature of
the study. Four different gels, randomly chosen among the seven prepared gels, were given to each
volunteer in non-transparent jars labeled with alphanumeric codes (double blind study).
The volunteers were instructed to apply each product (about 2 mg/cm2) onto different areas
over the back of their hands, twice a day, morning and evening, for two weeks, while refraining from
applying other products. Measurements of skin hydration and pigmentation were performed using the
specific probes of the instrument Soft Plus (Callegari Srl, Parma, Italy) under controlled temperature
(22 ± 1 ◦C) and humidity (35 ± 5%) conditions. Baseline values were determined prior to applying the
products. Skin hydration was evaluated by capacity measurements in the range of 0–100 u.c. (arbitrary
units) with a resolution of 1 u.c. and 5% precision. Skin pigmentation was analyzed using a probe
equipped with a double wavelength reflectance photometer (λ1 = 875 nm, λ2 = 660 nm), and values
were obtained in the range of 0–100 u.c., with a resolution of 1 u.c. and 5% precision.
Each measurement was performed in triplicate and the values were expressed as mean ± S.D.
2.13. Statistical Analyses
The statistical differences were evaluated for each parameter by the analysis of variance (ANOVA).
The differences among the mean values were subjected to the Student–Newman–Keuls test (SNK).
Before analysis, the degree of heterogeneity was assessed by Cochran’s test [29]. Data were processed
for one-way ANOVA using Statistica (version 8.0, Statsoft, Inc., Oklahoma).
3. Results and Discussion
3.1. Lipid Nanoparticle Characterization
As shown in Table 2, unloaded and IDE-loaded lipid nanoparticles, prepared by the PIT method,
showed small particle sizes (range: 23–42 nm), which were not significantly affected by IDE or VitE
loading. PDI values were lower than 0.300, suggesting the presence of a homogeneous population of
nanoparticles in the investigated samples. TEM analyses of the lipid nanocarriers under investigation
showed roughly spherical nanoparticles (Figure 1). As this technique gave information only about the
external surface of the nanocarrier, similar images were obtained for all nanoparticles. Therefore, we
reported as an example in Figure 1 TEM pictures of only SLN IDE1 and NLC IDE1.
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Table 2. Mean size (size), polydispersity index (PDI), zeta potential (ζ), and phase inversion
temperature (PIT) of unloaded and IDE-loaded SLN and NLC. IDE = idebenone, SLN = solid lipid
nanoparticles, NLC = nanostructured lipid carriers. Values are expressed as mean± standard deviation
(SD).
Code Size± SD (nm) PDI± SD ζ± SD (mV) PIT (◦C)
SLN 36.40 ± 0.30 0.260 ± 0.010 −1.56 ± 0.48 78
SLN IDE1 23.55 ± 1.08 0.266 ± 0.023 −2.02 ± 0.54 69
SLN IDE 1.5 42.33 ± 0.29 0.230 ±0.031 −2.01 ± 0.33 77
NLC 28.78 ± 0.90 0.235 ± 0.030 −2.00 ± 0.24 85
NLC IDE1 26.76 ± 0.33 0.178 ± 0.041 −1.99 ± 0.33 78
NLC IDE1.5 27.33 ± 0.55 0.198 ± 0.023 −2.32 ± 0.63 71
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showed a transition temperature (Tm) at 42 °C that was about 12 °C lower than that of the bulk lipid 
(cetyl palmitate), thus indicating the solid nature of the lipid in the nanocarrier matrix [31–33]. 
Unloaded SLN had a crystallinity index (CI) of 66%, which is in accordance with the results obtained 
in previous studies [12,23,34]. 
In the thermogram of unloaded NLC, we observed a Tm value lower than that of unloaded SLN 
that suggested a lesser crystalline structure of the nanocarrier core in the presence of the liquid lipid 
VitE. As expected, unloaded NLC had a CI (59%) lower than that of unloaded SLN. 
Loading 1% w/w IDE in these nanocarriers led to changes in the thermograms of the resulting 
lipid nanocarriers. In particular, a small shoulder at a temperature higher than Tm appeared in the 
DSC curve of SLN loaded with 1% w/w IDE, while the shoulder in the thermogram of unloaded NLC 
disappeared when 1% w/w IDE was loaded in these nanocarriers. 
Figure 1. i i s electron microscopy (TEM) images of SLN IDE1 (a) and NLC IDE1 (b).
IDE = idebenone, SLN = solid lipid nanoparticles, NLC = nanos ructured lipid carriers.
Although all these lipid nanoparticles showed low ζ-potential values (range: −1.56/−2.32 mV),
they proved stable after storage for two months at room te perature as no change of particle size
and PDI values were observed (data not shown). In addition, we did not observe any sign of drug
precipitation during storage. Similar low ζ-potential vales were obtained in previous works on SLN
with the same composition, an their good stability was attributed to their high PIT values [17,20,30].
I E loading into SLN and NLC was determined as the maximum amount of drug that could be
incorporated in the carriers leading to a clear colloidal system, as previously reported [17,20,30]. IDE
loading into SLN a d NLC was 1.5 and 2%, respectively. The higher IDE loadi g into NLC could be
attributed to the presence of the oil compone t that could favor both IDE solubilization in the lipid
matrix of the nanoparticles and a less ordered packing of t e NLC core.
DSC analyses of unloaded and IDE-loaded SLN and NLC pointed out different calorimetric
behaviors of these nanocarriers (Figure 2). As already reported in previous studies, unloaded SLN
showed a transition temperature (Tm) at 42 ◦C that was about 12 ◦C lower than that of the bulk
lipid (cetyl almitate), thus indicating the solid nature of the lipid in the nanocarrier matrix [31–33].
Unloaded SLN had a crystallinity index (CI) of 66%, whic is in accordance with the results obtained
in previous studies [12,23,34].
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Figure 2. Calorimetric curves, in heating mode, of the following lipid nanocarriers: (a) unloaded
solid lipid nanoparticles ( ), SLN loaded with idebenone (IDE) 1% w/w (SLN IDE 1), SLN loaded
with idebenone (IDE) 1.5% w/w (SLN IDE 1.5); (b) unloaded anostr ctured lipid carriers (NLC),
nanostructured lipid carriers loaded with IDE 1% w/w (NLC IDE 1), nanostructured lipid carriers
loaded with IDE 1.5% w/w (NLC IDE 1.5).
In the thermogram of unloaded NLC, we observed a Tm value lower than that of unloaded SLN
that suggested a lesser crystalline structure of the nanocarrier core in the presence of the liquid lipid
VitE. As expected, unloaded NLC had a CI (59%) lower than that of unloaded SLN.
Loading 1% w/w IDE in these nanocarriers led to changes in the thermograms of the resulting
lipid nanocarriers. In particular, a small shoulder at a temperature higher than Tm appeared in the
DSC curve of SLN loaded with 1% w/w IDE, while the shoulder in the thermogram of unloaded NLC
disappeared when 1% w/w IDE was loaded in these nanocarriers.
These results suggest that a stronger interaction of IDE with the lipid matrix of NLC is likely due
to the presence of the liquid component VitE. Loading IDE 1% w/w into SLN and NLC reduced the
CI of these nanocarriers (60% for SLN IDE1 and 55% for NLC IDE1). This behavior has already been
reported in literature (after incorporating different active compounds in lipid nanocarriers) [12,35].
The incorporation of IDE 1.5% w/w into SLN and NLC provided DSC curves similar to those
obtained from loading IDE 1% w/w (data not shown), and CI was not significantly affected for NLC
but was lower (57%) for SLN, thus supporting the hypothesis that NLC allowed a better incorporation
of IDE in the matrix of lipid nanoparticles.
3.2. Reducing Power
The reducing capacity of a compound indicates its potential antioxidant activity, as the presence of
reductants (such as antioxidant substances) in the samples causes the reduction of the Fe3+/ferricyanide
complex to the ferrous form. Therefore, Fe2+ can be monitored by measuring the formation of Perl’s
Prussian blue at 700 nm [36]. Figure 3 depicts the reducing power of the different percentages of
IDE loaded in SLN and NLC using the potassium ferricyanide reduction method, as reported in the
literature [24]. The reducing power of SLN after loading 1% or 1.5% w/w IDE increased with the
increase of the sample concentrations and showed a statistically significant greater value compared to
IDE-loaded NLC (p < 0.05).
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Figure 3. Reducing power of SLN, NLC, and samples loaded with 1% and 1.5% w/w of idebenone
(IDE). The letters b, c, and d indicate a sig ificant diff rence (p < 0.05) between samples loaded with
different concentrations of IDE and the samples of unloaded NLC and SLN (indicated with the letter a).
NLC = unloaded nanostructured lipid carrier; SLN = unloaded solid lipid nanoparticles; NLC-IDE 1
= NLC loaded with IDE 1% w/w; SLN-IDE 1 = SLN loaded with IDE 1% w/w; NLC-IDE 1.5 = NLC
loaded with IDE 1.5% w/w; SLN-IDE 1.5 = SLN loaded with IDE 1.5% w/w.
3.3. Free Radical Scavenging Activity
1,1-Diphenyl-2-picrylhydrazyl (DPPH) is a stable nitrogen-centered free radical that may convert
into 1,1-diphenyl-2-picrylhydrazine, a diamagnetic molecule, upon one-electron reduction. DPPH
has a strong absorption at 516 nm that decreases after the addition of reducing equivalents [37].
Experiments with sample concentrations in the range 5–100 mg/mL showed a decrease of DPPH
absorbance (Figure 4); in particular, SLN IDE1.5 had the highest activity at 100 mg/mL that was
significantly different from IDE-loaded NLC and SLN IDE1. The test showed greater antioxidant
activity of IDE-loaded SLN compared to IDE-loaded NLC, thus confirming the results obtained with
the potassium ferricyanide reduction method. The lower antioxidant activity of IDE-loaded NLC in
comparison to IDE-loaded SLN could be due to the stronger interaction of IDE with the lipid matrix
of NLC, which reduced IDE release from the nanoparticles and hence the antioxidant activity of the
resulting colloidal system.
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Figure 4. Antioxidant activity of IDE-loaded SLN and IDE-loaded NLC (5-100 g/mL) indicated as
percent (%) of DPPH radical inhibition. letters b and c indicate, for each concentration, a significant
difference (p < 0.05.) between th samples loaded with 1% or 1.5% w/w of idebenone (IDE) and the
samples of unl aded SLN and LC (indicated with the letter a). NLC = unloaded nanostructured
lipid carrier; SLN = unloaded solid lipi nanoparticles; NLC-IDE 1 = NLC loaded with IDE 1% w/w;
SLN-IDE 1 = SLN loaded with IDE 1% w/w; NLC-IDE 1.5 = NLC loaded with IDE 1.5% w/w; SLN-IDE
1.5 = SLN loaded with IDE 1.5% w/w.
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3.4. Evaluation of Cytotoxicity and Photo-Protective Effect in Fibroblast Cell Line HS-68
From a toxicological point of view, safety issues arise from nanomaterials with at least one
dimension smaller than 100 nm; therefore, SLNs are generally regarded as safe nanocarriers as they
commonly show particle sizes bigger than 100 nm and consist of well-tolerated ingredients [2,38].
As far as SLN topical application is concerned, Weyenberg et al. [39] reported that SLNs with positive
surface charge or containing stearic acid as a solid lipid showed significant cytotoxicity on mouse
fibroblast cells, HaCaT keratinocyte cells, or J774 macrophage cells used as model systems to evaluate
skin toxicity. On the contrary, Ridolfi et al. [40] did not observe any cytotoxicity in fibroblasts and
keratinocytes cells after treatment with SLN containing different lipid matrices.
In this work, we assessed the cytotoxic effects of the lipid nanocarriers under investigation
containing different percentages of IDE on human skin HS68 fibroblast cells.
Figure 5 shows the response of fibroblast cells exposed to increasing concentrations of different
IDE-loaded SLN and NLC. Results are expressed as a percentage of viable cells compared to the
control. Cell viability evaluations on sample concentrations in the range 10–100 µg/mL revealed that
the highest non-toxic concentration was 25 µg/mL, and for this reason, the experiment of induction
of oxidative stress was carried out with non-toxic concentrations of the samples. Figure 6 shows
that the exposure of cells to UV radiation, which were able to induce toxicity in this cell line in these
experimental conditions [26], determined a significant decrease of vitality, as calculated by the MTT
test (p < 0.05). On the contrary, treating the cells with 25 µg/mL of different IDE nanocarriers before
the exposure to UV light resulted in a notable photoprotective effect, as cell viability increased in a
dose-dependent manner compared to unprotected cells.
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Figure 5. Effect of increased doses of idebenone (IDE)-loaded solid lipid nanoparticles (SLN) and
nanostructured lipid carriers (NLC) on the percentage of vitality of HS68 fibroblast cells, determined
by MTT (each data is presented as mean ± SD; n=12). Statistical analysis for the comparison: * p < 0.05
vs. Co. Co = control (no treatment), NLC = unloaded nanostructured lipid carrier, SLN = unloaded
solid lipid nanoparticles, NLC-IDE 1 = NLC loaded with IDE 1% w/w; SLN-IDE 1 = SLN loaded with
IDE 1% w/w; NLC-IDE 1.5 = NLC loaded with IDE 1.5% w/w, SLN-IDE 1.5 = SLN loaded with IDE
1.5% w/w.
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Figure 6. Effect of IDE-loaded SLN and NLC on the vitality percentage of HS68 fibroblast cells exposed
to UV radiation: control cells not treated with compounds nd not exposed to UV (Co); cells treated
with UV radiation alone (UV); cells treated with 25 µg/mL of IDE-loade SLN or NLC and not exposed
to UV (25 µg/mL); cells pre-tr ated with IDE-loaded SLN or N C (25µg/mL) and subsequently
exposed to UV radiation (25 µg/mL + UV). Each ata is presente as mean ± SD (n = 12). Different
s perscript letters in icate a significa t difference compared to the control (p < 0.05).
3.5. In Vivo Topical Effects
Topical a plication of gel formulations containing unloaded SLN and NLC on human volunteers
resulted in an increase of skin hydration compared to the control vehicle (gel without lipid nanocarriers,
Figure 7). These results were in accordance with previous studies performed on similar formulations
and were attributed to the well-known occlusive properties of these lipid nanocarriers [11,12,41].
Loading different percentages of IDE into these lipid nanocarriers did not provide any significant
increase of skin hydration compared to unloaded SLN and NLC.
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Figure 7. Differences in skin hydration values (∆ hydration) obtained after a two-week in vivo topical
treatment with the gel u der investig tion. Statistical analysis for the comparison: * p < 0.05 vs. gel
C. Gel C = control gel (without lipid na ocarriers), Gel SLN = gel c ntaining unloaded solid ipid
nanoparticles (SLN), Gel NLC = gel co taining unloaded nanostructured l pid carriers, Gel SLN IDE1
= gel containing ideb none (IDE) 1% w/w loaded SLN, Gel IDE1.5 = gel containing IDE 1.5 % w/w
loaded SLN, Gel LC IDE1 = gel containing NLC loaded with IDE 1% w/w, Gel NLC IDE1.5 = gel
containing NLC loaded with IDE 1.5 % w/w.
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On the contrary, the incorporation of IDE into SLN and NLC provided a decrease in skin
pigmentation after treating human volunteers with gels containing such lipid nanocarriers for two
weeks (Figure 8). In particular, both IDE-loaded SLN (SLN IDE1 and SLN IDE1.5) led to similar
∆ pigmentation values that were higher than those obtained from applying the control gel or gels
containing unloaded SLN and NLC. A further decrease of skin pigmentation was observed from
loading IDE into NLC is likely due to the presence of tocopheryl acetate in these lipid nanocarriers
as the photo-protective effects of this vitamin are well-known [42]. Other authors pointed out an
increase of photo-protective efficacy in albino mice after loading IDE into NLC [43], thus supporting the
hypothesis that NLC could be regarded as suitable carriers for the development of topical formulations
with photo-protective activity. In our study, the in vivo topical effects of IDE-loaded SLN and NLC
were not dependent on IDE concentration in these lipid nanocarriers. Therefore, we have planned
further studies to investigate ID- loaded SLN and NLC interactions with skin tissue and the effects of
lipid nanocarrier composition on the photo-protective activity of such nanocarriers.
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properties (small particle sizes, low polydispersity indices, and good stability at room temperature). 
In vitro antioxidant assays (DPPH and reduction power) showed that, at the highest non-toxic 
concentration determined by the MTT test, the antioxidant activity of NLC containing different 
percentages of IDE (1.0 and 1.5 % w/w) was similar to that of SLN loaded with the same percentages 
of IDE. Analogously, similar photo-protective effects of IDE-loaded NLC and SLN were observed on 
HS68 fibroblast cells after exposure to UV light. The topical efficacy of these lipid nanocarriers 
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Figure 8. Decrease of skin pigmentation values (∆ pigmentation) obtained after a two-week in vivo
topical treatment with the gels under investigation. Statistical analysis for the comparison: * p < 0.05
vs. Gel C, Gel SLN, Gel NLC, Gel SLN IDE1, and Gel SLN IDE1.5. Gel C = control gel (without lipid
nanocarriers), Gel SLN = gel containing unloaded solid lipid nanoparticles (SLN), Gel NLC = gel
containing unloaded nanostructured lipid carriers, Gel SLN IDE1 = gel containing idebenone (IDE)
1% w/w loaded SLN, Gel IDE1.5 = gel containing IDE 1.5 % w/w loaded SLN, Gel NLC IDE1 = gel
containing NLC loaded with IDE 1% w/w, Gel NLC IDE1.5 = gel containing NLC loaded with IDE
1.5 % w/w.
4. Conclusions
IDE-loaded NLC containing tocopheryl acetate as the liquid lipid showed good technological
properties (small particle sizes, low polydispersity indices, and good stability at room temperature).
In vitro antioxidant assays (DPPH and r duction power) showed that, at the highest non-toxic
concentration determined by the MTT test, the antioxidant activity of NLC containing different
percen ages of IDE (1.0 and 1.5 % w/w) was similar to that of SLN loaded with the same percentages
of IDE. Anal gously, similar photo-protective effects of IDE-loaded NLC and SLN were observed on
HS68 fibroblast cells after exposure to UV light. The topical efficacy of these lipid nanocarriers loading
IDE was evaluated on hu an voluntee s from gel v hicles. The results of in vivo studies highlight a
greater photo-protective activity f IDE-l aded NLC compared to IDE-loaded SLN, thus suggesting a
synergic effect betw en IDE and tocopheryl acetate. Therefore, co-loading IDE and tocopheryl acetate
into NLC could be regarded as a promising approach to develop topical formulations with improved
photo-protective efficacy.
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